Newsroom
CARES Phase III clinical program did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosisMay 29, 2026
PUBLISHED 29 May 2026 AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients...
2026 Spring NewsletterApril 30, 2026
Be sure to catch up on the latest happenings in our spring newsletter here!
2026 Winter NewsletterJanuary 15, 2026
Be sure to catch up on the latest happenings in our winter newsletter here!
Light the Night for Amyloidosis March 2026: Shining a Beacon of Awareness and HopeJanuary 6, 2026
Each year, landmarks, homes, and communities across the country light up in red to honor those affected by amyloidosis and to raise awareness of this rare disease. Light the Night for Amyloidosis is a simple but powerful way to spark conversation, encourage earlier diagnosis, and show solidarity with patients, caregivers, families, and clinicians who are part of our community.
...Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid CardiomyopathyResults From ATTRibute-CM and Its Open-Label ExtensionNovember 12, 2025
JAMA Cardiol
Published Online: November 8, 2025
Today at the AHA congress in New Orleans, BridgeBio presented data showing that acoramidis significantly reduces all-cause mortality (through month 42) in people living with hereditary ATTR-CM population, with specific benefit noted in those living with the V122i variant. These data have also been published today in JAMA Cardiology.
You can read...